Breaking News
May 20, 2018 - Why drug users prefer heroin at home, but cocaine while out
May 20, 2018 - Gene therapy that reverses blindness in dogs could also help treat humans
May 20, 2018 - Opioid-Related Payments Linked to Increase in Opioid Rx
May 20, 2018 - Phone apps push people to take their pills
May 20, 2018 - Backbreaking Work May Shorten Men’s Lives
May 20, 2018 - Harsher drug laws won’t stop violence, argues former police chief
May 20, 2018 - Cognitive decline in dementia is not reduced by exercise
May 20, 2018 - Detecting breast cancer with non-invasive ‘disease screening pill’
May 20, 2018 - Simple treatment may minimize hearing loss triggered by loud noises
May 20, 2018 - Alignment of mother and offspring body clock could prevent diseases such as heart disease and obesity
May 20, 2018 - New commercial data warehouse for life sciences
May 20, 2018 - Practice Intervention Targeting IV Opioids May Cut Exposure
May 20, 2018 - New study provides insight into blood signatures of inflammation
May 20, 2018 - Scientists make breakthrough discovery about vitamin B12
May 20, 2018 - What Causes Cancer? Misconceptions Abound
May 20, 2018 - Proper burial of dead cells limits inflammation
May 20, 2018 - Study offers novel solution to suppress metastatic spread of deadly breast cancer
May 20, 2018 - Perspectives of patients and caregivers on care transitions
May 20, 2018 - Guidelines for weight gain in pregnancy should be changed for underweight and very obese women
May 20, 2018 - Researchers transplant retinal sheets derived from human embryonic stem cells in retinal degeneration mouse models
May 20, 2018 - U.S. military personnel at greater risk for skin cancer than general population
May 20, 2018 - Your immune system holds the line against repeat invaders, thanks to this molecule
May 20, 2018 - Between death and deportation
May 20, 2018 - Developing a High Throughput Mass Spectrometry Platform for Drug Discovery
May 19, 2018 - New project aims to increase awareness among hospital clinicians of non-beneficial treatment at end-of-life
May 19, 2018 - Automated bone scan index offers accurate, speedy prognostic information about prostate cancer
May 19, 2018 - Rutgers Cancer Institute nurses research various topics to enhance patient experience
May 19, 2018 - Computer models provide valuable insight to structure and function of Ebola, Zika viruses
May 19, 2018 - Study exposes key tactic used by deadly fungus
May 19, 2018 - Bacterial signals are crucial to development of pre-leukemic myeloproliferation, study shows
May 19, 2018 - Global experts identify key issues in supporting children with brain injuries transition back to school
May 19, 2018 - Social connections may protect black men who have sex with men from acquiring HIV
May 19, 2018 - Study IDs Factors Linked to Quality of Life With Dementia
May 19, 2018 - Potassium — Consumer
May 19, 2018 - HIV-1 viruses transmitted at birth are resistant to antibodies in mother’s blood
May 19, 2018 - Some water pitchers are much better at removing toxins, shows research
May 19, 2018 - Scientists discover how unusually long strands of RNA help colon cancer cells avoid death
May 19, 2018 - International study finds viable treatment option for people with mild asthma
May 19, 2018 - Mayo discovery could enable development of personalized ovarian, brain cancer treatments
May 19, 2018 - ‘Superbug’ Surfaces at Poultry Farm in China
May 19, 2018 - UCLA-designed program helps former HIV-positive inmates maintain health after release from jail
May 19, 2018 - New blood test could help avoid more than 40% of prostate biopsies, study finds
May 19, 2018 - Macrophages play key role in maintaining stem cell niche of mammary gland
May 19, 2018 - Ferritin Blood Test: MedlinePlus Lab Test Information
May 19, 2018 - Prolonged exposure to air pollution leads to genetic changes in rat brains, study finds
May 19, 2018 - Scientists identify new potential target to combat acute myeloid leukemia
May 19, 2018 - Ovarian cancer therapy may help treat patients with aggressive pancreatic cancer
May 19, 2018 - MediciNova Announces Opening of Investigational New Drug Application for MN-166 (ibudilast) in Glioblastoma
May 19, 2018 - Research shows that sexual activity and emotional closeness are unrelated to the rate of cognitive decline
May 19, 2018 - Nuffield Council on Bioethics outlines ethical issues arising from use of AI in healthcare
May 19, 2018 - Pancreatic cancer patients with BRCA1 or BRCA2 mutations fare better on platinum-based chemotherapy
May 19, 2018 - Tradeshow Talks with nal von minden Ltd
May 19, 2018 - Chemist begins new project to develop carbohydrate mimics to assist cancer therapies
May 19, 2018 - Healthy Lifestyle for Healthy Older Adults
May 19, 2018 - Epstein-Barr virus linked to seven serious diseases
May 19, 2018 - Biochemists isolate protein supercomplex from bacteria that generates voltage
May 19, 2018 - Mindfulness-based Stress Management Course for cancer survivors
May 19, 2018 - Simple screening tool can help identify people at increased risk for dementia
May 19, 2018 - Many gay and bisexual teenage boys use adult hookup apps to connect with friends, partners
May 19, 2018 - Maternal Exposure to Polluted Air Tied to Elevated Child BP
May 19, 2018 - Experimental drug extends survival in progeria
May 19, 2018 - FutureNeuro and GreenLight Medicines team up to develop cannabis-based treatments for epilepsies
May 19, 2018 - Brazilians with less education more likely to perceive as being in poor health
May 19, 2018 - Experts available to discuss subjects related to Ebola virus
May 19, 2018 - Opioid Makers’ Perks to Docs Tied to More Prescriptions
May 19, 2018 - AI detects patterns of gut microbes for cholera risk
May 19, 2018 - Researcher develops small molecules that inhibit derailment of gene expression in cancer
May 19, 2018 - Study brings fresh insights into biology of malaria parasite
May 19, 2018 - Microglia may play key role in slowing progression of prion diseases, research suggests
May 19, 2018 - Safety program successfully reduces SSIs in patients undergoing colorectal operations
May 19, 2018 - Clinical study supports usual medical care plus chiropractic care for low back pain
May 19, 2018 - Vermont legislators pass a drug importation law. So what?
May 19, 2018 - Trump proposes cutting planned parenthood funds. What does that mean?
May 19, 2018 - Cognitive training intervention reduces gait freezing in Parkinson’s patients, study shows
May 19, 2018 - Clinical trial begins enrollment to test safety of experimental MERS treatments
May 19, 2018 - Scientists disrupt two enzymes to shrink cancer cells
May 19, 2018 - 3D simulation reveals beneficial impact of medically induced brain cooling
May 19, 2018 - Natural antioxidant bilirubin may provide cardiovascular benefits
May 19, 2018 - Lash Group introduces latest solution for electronic benefit verification
May 19, 2018 - New CRISPR/Cas9 system targets regulatory genes of AIDS virus
U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

U.S. FDA approves first drug for patients with germline BRCA-mutated metastatic breast cancer

image_pdfDownload PDFimage_print

AstraZeneca and Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved LYNPARZA® (olaparib) for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor positive (HR+) breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Patients are selected for therapy based on an FDA-approved companion diagnostic from Myriad Genetics.

Dave Fredrickson, executive vice president, head of the oncology business unit, AstraZeneca, said, “This new approval for LYNPARZA makes it the first and only PARP inhibitor approved in metastatic breast cancer, and the only PARP inhibitor approved outside of ovarian cancer. This is significant for breast cancer patients, as the identification of BRCA status, in addition to hormone receptor and HER2 status, becomes a potentially critical step in the management of their disease.”

Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said, “This additional approval for LYNPARZA, based on the compelling data from the OlympiAD trial, represents an important advance for women with germline BRCA-mutated HER2-negative metastatic breast cancer, which is a difficult-to-treat cancer. Moreover, this approval adds further impetus to our important collaboration with AstraZeneca in developing cancer therapies.”

The approval was based on data from the randomized, open-label, phase 3 OlympiAD trial, which investigated LYNPARZA (olaparib) versus physician’s choice of chemotherapy (capecitabine, eribulin or vinorelbine). In the trial, LYNPARZA significantly prolonged progression-free survival (PFS) compared with chemotherapy, and reduced the risk of disease progression or death by 42 percent (HR 0.58; 95% CI 0.43-0.80; P=0.0009 median 7.0 vs 4.2 months). Patients with measurable disease taking LYNPARZA (n=167) experienced an objective response rate of 52 percent (95% CI 44-60), double the response rate for those in the chemotherapy arm (n=66), which was 23 percent (95% CI 13-35). Additionally, patients experienced a confirmed complete response rate of 7.8 percent for LYNPARZA compared to 1.5 percent for the chemotherapy arm. The data from the OlympiAD trial can be found in the June 2017 issue of the New England Journal of Medicine.

“Patients diagnosed with BRCA-related metastatic breast cancer are often younger than other breast cancer patients, and their disease is often much more aggressive and difficult to treat,” said Dr. Susan M. Domchek, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, and national leader on the OlympiAD trials. “While there is currently no cure for metastatic breast cancer, today’s approval offers a new, targeted option that may help to delay disease progression for these patients.”

Sue Friedman, executive director and founder of the nonprofit organization, Facing Our Risk of Cancer Empowered (FORCE), said, “We know there are limited treatment options for patients with metastatic breast cancer. For the portion of the 155,000 women in the U.S. living with metastatic breast cancer who have an inherited BRCA mutation, today’s news is encouraging. By undergoing genetic testing for BRCA mutations, we can gain critical information that will inform personalized treatment options specifically for women with this mutation.”

The most common adverse reactions in the OlympiAD trial of patients who received LYNPARZA were nausea (58%), anemia (40%), fatigue (including asthenia) (37%), vomiting (30%), neutropenia (27%), respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and headache (20%). The percentage of patients who discontinued treatment in the LYNPARZA arm was 5 percent compared to the chemotherapy arm, which was 8 percent.

This is the third indication approved for LYNPARZA (olaparib) in the U.S., where it has been used to treat nearly 4,000 advanced ovarian cancer patients. LYNPARZA has a broad clinical development program, and AstraZeneca and Merck are working together to deliver LYNPARZA as quickly as possible to more patients across multiple settings, including breast, ovarian, prostate and pancreatic cancers.

Source:

https://www.astrazeneca-us.com/

Tagged with:

About author

Related Articles